Joy Garrett

Ms. Joy Garrett


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2024 in Cancers
Verified
Journal Article
Open access
PDF file
PMPamela Lorena Mendoza- Munoz
Pamela Lorena Mendoza- Munoz
Narvadeshwar KushwahaNarvadeshwar Kushwaha
Narvadeshwar Kushwaha
DCDineshsinha Chauhan
Dineshsinha Chauhan
KGKarim Ben Ali Gacem
Karim Ben Ali Gacem
JGJoy Garrett
Joy Garrett
John J. TurchiJohn J. Turchi
John J. Turchi
Background: DNA-dependent protein kinase (DNA-PK) is a validated cancer therapeutic target involved in DNA damage response (DDR) and non-homologous end-joining (NHEJ) repair of DNA double-strand breaks (DSBs). Ku serves as a sensor of DSBs by binding to DNA ends and activating DNA-PK. Inhibition of DNA-PK is a common strategy to block DSB repair and improve efficacy of ionizing radiation (IR) therapy and radiomimetic drug therapies. We have previously developed Ku–DNA binding inhibitors (Ku-DBis) that block in vitro and cellular NHEJ activity, abrogate DNA-PK autophosphorylation, and potentiate cellular sensitivity to IR. Results and Conclusions: Here we report the discovery of oxindole Ku-DBis with improved cellular uptake and retained potent Ku-inhibitory activity. Variable monotherapy activity was observed in a panel of non-small cell lung cancer (NSCLC) cell lines, with ATM-null cells being the most sensitive and showing synergy with IR. BRCA1-deficient cells were resistant to single-agent treatment and antagonistic when combined with DSB-generating therapies. In vivo studies in an NSCLC xenograft model demonstrated that the Ku-DBi treatment blocked IR-dependent DNA-PKcs autophosphorylation, modulated DDR, and reduced tumor cell proliferation. This represents the first in vivo demonstration of a Ku-targeted DNA-binding inhibitor impacting IR response and highlights the potential therapeutic utility of Ku-DBis for cancer treatment.

Verified
Journal Article
Open access
PDF file
SAShahnur Ahmed
Shahnur Ahmed
MMMohan Mohan
Mohan Mohan
ASAngad Singh Sidhu
Angad Singh Sidhu
DKDaniel J Konig
Daniel J Konig
CSChristopher Aldrine Subi-Kasozi
Christopher Aldrine Subi-Kasozi
AHAladdin H. Hassanein
Aladdin H. Hassanein
Lymphedema is chronic swelling from lymphatic dysfunction. The vascular delay phenomenon is used in flap reconstruction to increase flap viability through staged selective partial disruption of blood supply to enhance flap survival, followed by flap transfer 7–10 days later. A similar corollary for lymphatics remains unknown. The purpose of this study was to evaluate whether lymphatic preconditioning with staged disruption of lymphatics in the murine hindlimb lymphedema model can be protective against lymphedema. C57BL/6 mice underwent 20 Gy hindlimb irradiation. Group 1 (immediate lymphatic disruption) underwent a circumferential skin incision, complete lymphatic disruption, and popliteal lymph node excision in a single-stage operation. Group 2 (delayed lymphatic disruption) underwent a semi-circumferential inguinal skin incision and dominant lymphatic transection and, 7 days later, received a circumferential skin incision, complete lymphatic transection, and popliteal lymphadenectomy. Paw thickness was measured weekly. Near-infrared laser lymphangiography and immunohistochemistry were performed on D35. Group 2 had a lower average paw thickness (p = 0.0008) and greater lymphatic clearance signal intensity at 24 h (p = 0.0035). Immunohistochemistry indicated an abundance of the lymphatic endothelial-specific marker podoplanin in Group 2 compared to Group 1 (p = 0.03). This study demonstrates evidence for a novel concept of a lymphatic delay phenomenon parallel to the well-known vascular delay phenomenon.